Pacira BioSciences Files Q3 2024 10-Q

TL;DR

Pacira BioSciences filed its Q3 2024 10-Q, check financials.

AI Summary

Pacira BioSciences, Inc. filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and business operations for the third quarter and the year-to-date period. Specific financial figures and operational highlights are presented within the report.

Why It Matters

This filing provides investors with an update on Pacira BioSciences' financial health and operational progress, crucial for understanding the company's performance and future outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Pacira BioSciences faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.

Key Players & Entities

• Pacira BioSciences, Inc. (company) — Filer of the 10-Q
• 20240930 (date) — End of the reporting period
• 20241106 (date) — Filing date
• Pacira Pharmaceuticals, Inc. (company) — Former company name
• Blue Acquisition Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Mar

Filing Documents

• pcrx-20240930.htm (10-Q) — 1646KB
• exhibit103-laurenrikeramen.htm (EX-10.3) — 14KB
• exhibit104-laurenrikeramen.htm (EX-10.4) — 35KB
• exhibit105-charlesareinhar.htm (EX-10.5) — 101KB
• ex106-ar2014inducementplan.htm (EX-10.6) — 87KB
• ex107-ar2014inducementplan.htm (EX-10.7) — 26KB
• ex108-ar2014inducementplan.htm (EX-10.8) — 37KB
• pcrx-9302024xex311.htm (EX-31.1) — 12KB
• pcrx-9302024xex312.htm (EX-31.2) — 12KB
• pcrx-9302024xex321.htm (EX-32.1) — 8KB
• pcrx-20240930_g1.jpg (GRAPHIC) — 27KB
• pcrx-20240930_g2.jpg (GRAPHIC) — 133KB
• 0001396814-24-000141.txt ( ) — 10156KB
• pcrx-20240930.xsd (EX-101.SCH) — 57KB
• pcrx-20240930_cal.xml (EX-101.CAL) — 86KB
• pcrx-20240930_def.xml (EX-101.DEF) — 387KB
• pcrx-20240930_lab.xml (EX-101.LAB) — 781KB
• pcrx-20240930_pre.xml (EX-101.PRE) — 581KB
• pcrx-20240930_htm.xml (XML) — 1409KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 4 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statements of Comprehensive (Loss) Income 6 Condensed Consolidated Statements of Stockholders' Equity 7 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 50 Item 4.

Controls and Procedures

Controls and Procedures 51

OTHER INFORMATION

PART II. OTHER INFORMATION 51 Item 1.

Legal Proceedings

Legal Proceedings 51 Item 1A.

Risk Factors

Risk Factors 51 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 51 Item 3. Defaults Upon Senior Securities 51 Item 4. Mine Safety Disclosures 52 Item 5. Other Information 52 Item 6. Exhibits 52

Signatures

Signatures 54 Pacira BioSciences, Inc. | Q3 2024 Form 10-Q | Page 3 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS (Unaudited)

Item 1. FINANCIAL STATEMENTS (Unaudited) PACIRA BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 245,965 $ 153,298 Short-term available-for-sale investments 207,845 125,283 Accounts receivable, net 100,653 105,556 Inventories, net 111,865 104,353 Prepaid expenses and other current assets 23,641 21,504 Total current assets 689,969 509,994 Noncurrent available-for-sale investments — 2,410 Fixed assets, net 166,852 173,927 Right-of-use assets, net 53,830 61,020 Goodwill — 163,243 Intangible assets, net 440,292 483,258 Deferred tax assets 134,022 144,485 Investments and other assets 36,726 36,049 Total assets $ 1,521,691 $ 1,574,386 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 19,367 $ 15,698 Accrued expenses 76,377 64,243 Lease liabilities 9,191 8,801 Current portion of convertible senior notes, net 201,466 8,641 Total current liabilities 306,401 97,383 Convertible senior notes, net 278,867 398,594 Long-term debt, net 107,024 115,202 Lease liabilities 47,875 54,806 Contingent consideration 19,157 24,698 Other liabilities 12,784 13,573 Total liabilities 772,108 704,256 Commitments and contingencies (Note 15) Stockholders' equity: Preferred stock, par value $ 0.001 ; 5,000,000 shares authorized; none issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, par value $ 0.001 ; 250,000,000 shares authorized; 46,985,386 shares issued and 46,148,146 shares outstanding at September 30, 2024 and 46,481,174 shares issued and outstanding at December 31, 2023 47 46 Treasury stock, at cost, 837,240 and zero shares at September 30, 2024 and December 31, 2023, respectively, inclusive of excise tax ( 25,121 ) — Additional paid-in capital 996,376 976,633 Accumulated deficit ( 222,397 ) ( 106,796 ) Accumulated other compr

View Full Filing

View this 10-Q filing on SEC EDGAR